Publications by authors named "D Perron"
Phospholipase D2 (PLD2), a major isoform of the PLD family, has been reported to regulate inflammatory responses. Thus far, the relevance of PLD2 in psoriasis, an inflammatory skin disease, has not been explored. In the current study, we examined PLD2 expression in the skin of psoriasis patients and the role of PLD2 in an interleukin (IL)-23-induced mouse model of psoriasiform dermatitis.
View Article and Find Full Text PDFArticle Synopsis
- The article explores the importance of interprofessional collaboration (IPC) in primary health care (PHC), especially in rural and remote areas, highlighting a lack of research on effective initiatives.
- A scoping review of 94 articles resulted in 23 relevant studies, finding that while ten focused on implementing IPC initiatives, most discussed the barriers and facilitators to these efforts.
- Key barriers included limited human resources and unclear roles, while facilitators like team size and community connections showed promise for enhancing IPC in these challenging clinical environments.
Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability, IL-23 binding affinity, inhibitory-binding mode, potency and efficacy. Risankizumab and guselkumab exhibited 5-fold higher affinity for IL-23 and showed more potent inhibition of IL-23 signaling than ustekinumab and tildrakizumab.
View Article and Find Full Text PDFPsoriasis is a debilitating skin disease characterized by epidermal thickening, abnormal keratinocyte differentiation, and proinflammatory immune cell infiltrate into the affected skin. IL-17A plays a critical role in the etiology of psoriasis. ACT1, an intracellular adaptor protein and a putative ubiquitin E3 ligase, is essential for signal transduction downstream of the IL-17A receptor.
View Article and Find Full Text PDF